Cingulate Reports Q2 2026 Results: $28.4M Cash Runway Through Mid-2027, NDA Resubmission in Progress
CING sits 62% above its 52-week low of $3.16 on light trading volume (0.2× avg).
Summary
Cingulate reported Q2 2026 financial results with $28.4 million in cash providing runway through mid-2027, and provided updates on CTx-1301 NDA resubmission progress and commercial readiness.
Key Events · Earnings and Guidance · CING
-
Q2 2026 Financial Results
Net loss of $5.9 million for Q2 2026 and $15.2 million for H1 2026, compared to $5.0 million and $8.8 million in the prior-year periods.
-
Cash Runway Extended
Cash and cash equivalents of $28.4 million as of June 30, 2026, up from $11.0 million at year-end 2025, providing runway through mid-2027.
-
NDA Resubmission Progress
Company is completing CMC work requested in the FDA's Complete Response Letter and plans to resubmit the CTx-1301 NDA as promptly as practicable.
-
Commercial Distribution Agreement
Signed exclusive services agreement with Prasco, LLC on July 21, 2026 to establish commercial distribution infrastructure for CTx-1301 launch.
Analysis · CING · Life Sciences
Cingulate's Q2 2026 results show a net loss of $5.9 million, but the company holds $28.4 million in cash, extending its runway through mid-2027. The company is advancing CMC work to resubmit its CTx-1301 NDA after the FDA's Complete Response Letter, and it has signed a distribution agreement with Prasco to prepare for commercial launch. SG&A expenses more than doubled year-over-year as the company builds out commercial infrastructure, while R&D spending declined. The cash position and operational progress are critical for a pre-revenue biotech facing regulatory uncertainty.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $5.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.2M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.